氧利平素对缺血性中风的影响:从病理生理学到临床表型
Liuyang Cheng1, Jian Xia2,3
1Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, P.R. China.
Metabolomics : Official journal of the Metabolomic Society
|October 16, 2025
概括
氧利平素是PUFA的脂质代谢物,在缺血性中风病理生理学中起着复杂的作用. 了解氧利平调节为中风患者提供了潜在的治疗策略.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 利皮多米克 (Lipidomics) 是一种消化剂.
背景情况:
- 缺血性中风是导致死亡和残疾的主要原因.
- 来自omega-3和omega-6多不和脂肪酸 (PUFA) 的氧利平是生物活性脂质代谢产物.
- 在缺血性中风中报告了氧利平的保护性和有害作用,临床相关性越来越大.
研究的目的:
- 审查氧利平生物合成,信号传递,以及它们对缺血性中风病理生理学的调节.
- 探索氧利平对临床中风表型的影响.
- 讨论针对氧利平调节的潜在治疗方法.
主要方法:
- 对有关氧利平和缺血性中风的现有文献进行系统审查.
- 阐明氧利平子类在中风病原性中的作用.
- 分析氧利平与临床中风表型之间的关联.
主要成果:
- 氧利平因与缺血性中风的关键病理生理机制有关,包括炎症,氧化应激,免疫反应,血栓形成,亡和血管失调.
- 氧利平蛋白配置文件和缺血性中风表型之间存在明显的关联.
- 需要进一步的代谢学研究来确定特定的氧利生物标志物.
结论:
- 氧利平调节是缺血性中风的一个关键因素.
- 氧利平是脂质组研究和中风治疗开发的一个有前途的领域.
- 将氧利平研究转化为临床干预需要进一步确定和验证生物标志物.
相关概念视频
Coronary Artery Disease II: Pathophysiology
366
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
366
Atherosclerosis I: Introduction
904
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
904
Ischemic Heart Disease: Overview
2.9K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.9K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
351
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
351
Oxidation of Phenols to Quinones
4.5K
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
4.5K
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319


